CRNA

Providence Alaska Medical Center first in Alaska to offer breakthrough treatment for neuroendocrine tumors. Lutathera targets cancers that develop in pancreas, stomach, intestines, and other parts of the digestive system. ANCHORAGE, Alaska - Providence Alaska Medical Center recently became the first in Alaska to offer a breakthrough treatment for a complex group of cancers that can develop in the pancreas, stomach, intestines, and other parts of the digestive system. Lutathera is a targeted therapy that identifies and kills or reduces cancer cells in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Lutathera is approved for the treatment of adults and pediatric patients aged 12 and older with somatostatin receptor-positive forms of these tumors. "Lutathera is a new, advanced medication that targets cancer cells at the molecular level," said Stephen Settle, M.D., Ph.D., a radiation oncologist at PAMC. "This medication targets radiation specifically to cancer cells, leaving healthy normal cells intact. Think of it like a key that only fits the lock of the cancer cells and goes anywhere in the body to go after them." Lutathera is administered via infusion and works by acting as a targeted radioligand therapy, which uses a targeting molecule to find specific cancer cells and a radioactive particle to deliver a precise dose of radiation directly to those cells. Patients typically receive four treatments given once every eight weeks. Before treatment, patients receive an amino acid infusion that helps protect the kidneys from radiation exposure. The entire treatment course usually takes about eight months to complete. Patients continue receiving standard treatment for GEP-NETs during and after Lutathera. "Before we launched this program at Providence Alaska Medical Center, patients had to travel to the Lower 48 every eight weeks for four treatments and remain there for three days after each dose before returning home," said John Halligan, M.D., radiation oncologist and medical director of Radiation Oncology with Providence Cancer Center. "That made access to this highly effective treatment extremely challenging for Alaskans." "We expect to treat five to 10 patients each year, and while that number is small, we believe it is absolutely worthwhile because of the meaningful impact this therapy can have on patients' lives," Halligan added. According to the National Cancer Institute, Lutathera is the first radioactive drug approved to treat these rare cancers. In the past, patients with cancerous GEP-NETs had limited treatment options if initial therapy failed to keep the cancer from growing or progressing. "For many patients, the previous option was octreotide, which helps manage symptoms such as flushing, diarrhea, abdominal cramping, asthma-like symptoms, racing heart and increased blood pressure. However, it does very little to stop tumor growth," said Halligan. "In the landmark NETTER-1 trial, the two-year progression-free survival rate was 65% for patients treated with Lutathera, compared to just 11% for patients receiving octreotide alone. In addition, Lutathera is usually very well tolerated compared to chemotherapy." In 2025, Providence became the first treatment center in Alaska to offer Pluvicto, an innovative, targeted radiopharmaceutical therapy for men with advanced, metastatic prostate cancer. "There are many more radioligand drugs currently in development and we expect to see other success stories like this in the years to come, said Settle. "Such radioligand drugs are going to be a real game-changer for patients, and we want Alaskans to be able to get these treatments right here at home." About Providence Alaska Medical Center Providence Alaska Medical Center, a nationally recognized trauma center and Alaska's only Magnet hospital, is part of Providence, a not-for-profit network of hospitals, care centers, health plans, physicians, clinics, home health services, affiliated services and educational facilities. For more information, visit providence.org/locations/ak/alaska-medical-center.

Applied Biologics announces extension of longstanding system-wide agreement with Providence Health & Services for XWRAP(R). SCOTTSDALE, Ariz., July 27, 2026 (GLOBE NEWSWIRE) - Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the extension of its longstanding system-wide purchase agreement with Providence Health & Services for XWRAP(R). The agreement reinforces the Company's ongoing relationship with one of the nation's largest integrated health systems and supports continued access to XWRAP across participating Providence facilities and affiliated organizations. The extension builds upon a relationship between Applied Biologics and Providence Health & Services that began in 2015 and reflects the Company's continued commitment to supporting physicians and healthcare professionals caring for patients across a broad network of hospitals, outpatient facilities, and affiliated healthcare organizations. XWRAP is Applied Biologics' placental-derived wound cover used in the management of chronic wounds and as a tissue-plane barrier during surgical procedures. The Company continues to expand access to XWRAP through collaborations with integrated health systems, federal healthcare systems, hospitals, ambulatory surgery centers, wound care centers, and other healthcare providers throughout the United States. "We are proud to continue our longstanding relationship with Providence Health & Services and appreciate their continued confidence in XWRAP," said Edward Britt, Chief Executive Officer of Applied Biologics. "Long-term relationships with leading health systems are earned through consistent product quality, dependable customer support, and an unwavering commitment to building high-quality scientific and clinical evidence. We remain focused on supporting physicians with innovative technologies backed by rigorous clinical research." Jacob Pollak, Chief Operating Officer of Applied Biologics, added, "Health system partnerships are an important component of our long-term commercial strategy. The continued extension of our relationship with Providence reflects our commitment to providing responsive customer service, dependable product availability, and meaningful support for clinicians across a broad range of care settings. As we continue expanding our national market access initiatives, we remain focused on making XWRAP accessible to physicians and healthcare providers wherever patients receive care." Applied Biologics continues to strengthen the scientific and clinical foundation supporting XWRAP through prospective randomized controlled clinical trials, real-world evidence initiatives, translational research, peer-reviewed publications, and expanded clinical applications in both chronic wound management and surgery. About XWRAP(R) XWRAP is a placental-derived wound cover used in the management of chronic wounds and as a tissue-plane barrier during surgical procedures. Applied Biologics continues to expand the scientific and clinical evidence supporting XWRAP through prospective randomized controlled clinical trials, translational research, peer-reviewed publications, real-world evidence studies, and ongoing clinical research. About Applied Biologics Applied Biologics is a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs. The Company's pipeline includes programs focused on chronic wounds, degenerative diseases, immunology, and regenerative medicine. Applied Biologics is committed to advancing innovative therapies through rigorous scientific development, clinical validation, and regulatory excellence. Forward-Looking Statements This press release contains forward-looking statements regarding commercial relationships, health system collaborations, market access initiatives, scientific research, and future business prospects. Actual results may differ materially from those expressed or implied due to various risks and uncertainties.

Providence Alaska Medical Center earns SRC's Center of Excellence in Robotic Surgery accreditation. Hospital recognized for meeting rigorous national and international standards for robotic surgery. Anchorage, Alaska - Providence Alaska Medical Center has achieved accreditation from the Surgical Review Corporation (SRC) as a Center of Excellence in Robotic Surgery. As an SRC accredited Center of Excellence, PAMC meets both nationally and internationally recognized standards for robotic surgery. Accreditation requires hospitals to meet rigorous, measurable standards across volume, outcomes, infrastructure and care delivery. The robotic surgery program at PAMC began providing robot-assisted surgery in 2000 and recently surpassed 10,000 robotic surgeries performed. "Earning this accreditation gives patients confidence they are receiving advanced, high-quality care from an experienced team," said Daniel Rossi, D.O., leader of the Robotics steering committee at Providence. "It also reflects our ongoing commitment to excellence in safety, innovation and clinical quality." SRC is an internationally recognized, independent accreditation body that evaluates surgical quality and patient safety, accrediting hundreds of leading hospitals and surgical facilities across the United States and globally. PAMC continues to invest in robotic technology. In 2025, the hospital added the da Vinci 5, the newest model of the robot console that allows surgeons to perform minimally invasive procedures using several small incisions. For patients, this means shorter recovery times and fewer risks of postoperative complications. "This distinction highlights Providence as a leader in delivering advanced surgical care in Alaska, where access to specialized services can be limited by geography," said Kristen Solana Walkinshaw, M.D., chief medical officer of Providence Alaska. "By investing in robotic technology and maintaining high clinical standards, Providence is helping ensure patients can receive complex care close to home." Healthcare facilities and surgeons seeking an SRC accreditation undergo an extensive assessment and inspection process to ensure the applicant meets SRC's proven standards and requirements. These requirements include surgical volumes, facility equipment, clinical pathways and standardized operating procedures, and an emphasis on patient education and continuous quality assessment. Inspectors also educate staff in the accredited departments on best practices to help an organization improve its care and services. "We're proud to recognize Providence Alaska Medical Center for its commitment to advancing and providing quality care for all patients," said Gary M. Pratt, CEO of SRC. "This accreditation signals that this facility is among the best in this specialty and is dedicated to delivering the highest level of care possible." About Providence Alaska Medical Center Providence Alaska Medical Center, a nationally recognized trauma center and Alaska's only Magnet hospital, is part of Providence, a not-for-profit network of hospitals, care centers, health plans, physicians, clinics, home health services, affiliated services and educational facilities. For more information, visit providence.org/locations/ak/alaska-medical-center. About Surgical Review Corporation Established in 2003, Surgical Review Corporation (SRC) is an internationally recognized, nonprofit, patient safety organization dedicated to recognizing and refining surgical care. SRC accredits the top hospitals, surgeons and health professionals worldwide that meet its proven standards. Look for its seal, expect excellence. For more information, visit www.surgicalreview.org.